Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03755791
Title Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy (COSMIC-312)
Acronym COSMIC-312
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Exelixis
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | TUR | ROU | POL | NZL | NLD | ITA | ISR | IRL | HUN | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG


No variant requirements are available.